MEREO BIOPHARMA GROUP PLC Amortization of Intangible Assets
MEREO BIOPHARMA GROUP PLC (MREO) reported Amortization of Intangible Assets of $254.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-11
- MEREO BIOPHARMA GROUP PLC amortization of intangible assets for the quarter ending 2026-06-30 was $127.00K, a 7.63% increase year-over-year.
- MEREO BIOPHARMA GROUP PLC amortization of intangible assets for the quarter ending 2026-03-31 was $127.00K, a 19.81% increase year-over-year.
- MEREO BIOPHARMA GROUP PLC amortization of intangible assets for the quarter ending 2025-12-31 was $424.00K, a 285.45% increase year-over-year.
- MEREO BIOPHARMA GROUP PLC amortization of intangible assets for the quarter ending 2025-09-30 was -$183.00K, a 263.39% decline year-over-year.
- MEREO BIOPHARMA GROUP PLC amortization of intangible assets for fiscal 2025 was $465.00K, a 6.16% increase from fiscal 2024.
- MEREO BIOPHARMA GROUP PLC amortization of intangible assets for fiscal 2024 was $438.00K, a 10.89% increase from fiscal 2023.
- MEREO BIOPHARMA GROUP PLC amortization of intangible assets for fiscal 2023 was $395.00K.
- MEREO BIOPHARMA GROUP PLC amortization of intangible assets for fiscal 2022 was $0.00.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $127.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $254.00K 10-Q · filed 2026-08-11 | $678.00K derived: sum of 3 quarters · filed 2026-08-11 | $495.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $127.00K 10-Q · filed 2026-05-12 | $551.00K derived: sum of 2 quarters · filed 2026-05-12 | $368.00K derived: sum of 3 quarters · filed 2026-05-12 | $486.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $424.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $241.00K derived: sum of 2 quarters · filed 2026-03-19 | $359.00K derived: sum of 3 quarters · filed 2026-08-11 | $465.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | -$183.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$65.00K derived: sum of 2 quarters · filed 2026-08-11 | $41.00K 10-Q · filed 2025-11-10 | $151.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $118.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $224.00K 10-Q · filed 2026-08-11 | $334.00K derived: sum of 3 quarters · filed 2026-08-11 | $446.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $106.00K 10-Q · filed 2026-05-12 | $216.00K derived: sum of 2 quarters · filed 2026-05-12 | $328.00K derived: sum of 3 quarters · filed 2026-05-12 | $436.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $110.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $222.00K derived: sum of 2 quarters · filed 2026-03-19 | $330.00K derived: sum of 3 quarters · filed 2026-03-19 | $438.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $112.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $220.00K derived: sum of 2 quarters · filed 2025-11-10 | $328.00K 10-Q · filed 2025-11-10 | $443.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $108.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $216.00K 10-Q · filed 2025-08-12 | $331.00K derived: sum of 3 quarters · filed 2025-08-12 | $440.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $108.00K 10-Q · filed 2025-05-13 | $223.00K derived: sum of 2 quarters · filed 2025-05-13 | $332.00K derived: sum of 3 quarters · filed 2025-05-13 | $439.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $115.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $224.00K derived: sum of 2 quarters · filed 2025-03-26 | $331.00K derived: sum of 3 quarters · filed 2025-03-26 | $395.00K 10-K · filed 2025-03-26 |
| 2023-09-30 | $109.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $216.00K derived: sum of 2 quarters · filed 2024-11-12 | $280.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $107.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $171.00K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $64.00K 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |